Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | MME | P08473 | 7/20 | 0.47 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 5/20 | 0.43 |
| ▸ | ACE | P12821 | 4/20 | 0.43 |
| ▸ | CPA1 | P15085 | 3/20 | 0.43 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.43 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20446011 | 1.00 | CA2 (0.53) | CA2MMEPPARGNOS2ACE2 | |
| SCHEMBL30511891 | 0.86 | FOLH1 (0.57) | CA2MMENOS2ACE2ACE | |
| SCHEMBL1097344 | 0.86 | FOLH1 (0.57) | CA2MMENOS2ACE2ACE | |
| SCHEMBL1097343 | 0.86 | FOLH1 (0.57) | CA2MMENOS2ACE2ACE | |
| SCHEMBL1135183 | 0.86 | MME (0.58) | MMENOS2ACE2ACECPA1 | |
| SCHEMBL29214532 | 0.86 | MME (0.58) | MMENOS2ACE2ACECPA1 | |
| SCHEMBL1135185 | 0.86 | MME (0.58) | MMENOS2ACE2ACECPA1 | |
| SCHEMBL31256909 | 0.82 | PPID (0.50) | NOS2 | |
| SCHEMBL29904332 | 0.81 | PPARG (0.49) | CA2MMEPPARGNOS2ACE2 | |
| SCHEMBL20578232 | 0.81 | CA2 (0.58) | CA2MMEACE2ACECPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12558432-B2 | Biocompatible polymeric drug carriers for delivering active agents | CIS BIOPHARMA AG (CH) | 2026-02-24 | — | — | US | disclosed |
| US-20220409737-A1 | BIOCOMPATIBLE POLYMERIC DRUG CARRIERS FOR DELIVERING ACTIVE AGENTS | CIS BIOPHARMA AG (CH) | 2022-12-29 | — | — | US | disclosed |
| EP-4051320-A1 | BIOCOMPATIBLE POLYMERIC DRUG CARRIERS FOR DELIVERING ACTIVE AGENTS | CIS Pharma AG (CH) | 2022-09-07 | — | — | EP | disclosed |
| CN-114641316-A | Biocompatible polymeric drug carriers for delivery of active agents | CIS制药股份公司 | 2022-06-17 | — | — | CN | disclosed |
| US-11008414-B2 | Polymer materials for contact lens applications | CIS PHARMA AG (CH) | 2021-05-18 | — | — | US | disclosed |
| US-20210128735-A1 | BIOCOMPATIBLE COPOLYMER CONTAINING MULTIPLE ACTIVE AGENT MOLECULES | CIS BIOPHARMA AG (CH) | 2021-05-06 | — | — | US | disclosed |
| WO-2021084087-A1 | BIOCOMPATIBLE POLYMERIC DRUG CARRIERS FOR DELIVERING ACTIVE AGENTS | CIS PHARMA AG (CH) | 2021-05-06 | — | — | WO | disclosed |
| EP-3790590-A1 | BIOCOMPATIBLE COPOLYMER CONTAINING MULTIPLE ACTIVE AGENT MOLECULES | CIS Pharma AG (CH) | 2021-03-17 | — | — | EP | disclosed |
| CN-112088016-A | Biocompatible copolymers containing multiple active agent molecules | 化工研究所有限公司 | 2020-12-15 | — | — | CN | disclosed |
| US-20200283560-A1 | New polymer materials for contact lens applications | CIS PHARMA AG (CH) | 2020-09-10 | — | — | US | disclosed |
| WO-2019215207-A1 | BIOCOMPATIBLE COPOLYMER CONTAINING MULTIPLE ACTIVE AGENT MOLECULES | CIS PHARMA AG (CH) | 2019-11-14 | — | — | WO | disclosed |
| EP-3356433-B1 | NEW POLYMER MATERIALS FOR CONTACT LENS APPLICATIONS | CIS PHARMA AG (CH) | 2019-09-18 | — | — | EP | disclosed |
| EP-3356433-A1 | NEW POLYMER MATERIALS FOR CONTACT LENS APPLICATIONS | CIS Pharma AG (CH) | 2018-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12558432-B2 | Biocompatible polymeric drug carriers for delivering active agents | MSR1, CD47, SLC43A1 | CA2 78/4885MME 2405/4885PPARG 4321/4885 |
| US-20220409737-A1 | BIOCOMPATIBLE POLYMERIC DRUG CARRIERS FOR DELIVERING ACTIVE AGENTS | CD47, DNPEP, MSR1 | CA2 236/4885MME 426/4885PPARG 4182/4885 |
| US-20210128735-A1 | BIOCOMPATIBLE COPOLYMER CONTAINING MULTIPLE ACTIVE AGENT MOLECULES | LNPEP, PAICS, CD47 | CA2 760/4885MME 741/4885PPARG 3190/4885 |
| US-20200283560-A1 | New polymer materials for contact lens applications | CRYAA, CRYAB, BCAT1 | CA2 1512/4885MME 2794/4885PPARG 3372/4885 |
| US-11008414-B2 | Polymer materials for contact lens applications | CRYAA, BCAT1, CRYAB | CA2 1537/4885MME 2887/4885PPARG 3350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.